Courtney Flaherty

1 day ago | onclive.com | Courtney Flaherty

The combination of AlloNK (AB-101) plus rituximab (Rituxan) produced high complete response (CR) rates and prolonged responses beyond 12 months in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-cell NHL), according to updated data from a phase 1/2 trial(NCT04673617) presented at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting.1Among patients who received AlloNK plus rituximab and were naive to prior CAR T-cell therapy (n = 14), the CR rate was 64%.

2 days ago | onclive.com | Courtney Flaherty

Despite decades of research, the standard of care (SOC) for patients with advanced ovarian cancer has remained largely unchanged for the past 25 years, and women diagnosed with this malignancy continue to face high rates of recurrence and poor prognoses.1 Clinical progress has been particularly limited in the domain of immunotherapy, where checkpoint inhibitors have repeatedly failed to demonstrate consistent survival benefits.2 This has somewhat tempered initial interest in developing...

6 days ago | cancernetwork.com | Courtney Flaherty

Early clinical activity and tolerability were reported in a small cohort of patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) who received fruquintinib (Fruzaqla) in combination with capecitabine (Xeloda), according to data from a phase 1/2 study (NCT05016869) presented at the 2025 American Association for Cancer Research Annual Meeting.

6 days ago | onclive.com | Courtney Flaherty

Treatment with TT1-101, was well tolerated and showed clinically meaningful antitumor activity, including confirmed partial responses (cPRs), in patients with advanced metastatic hepatocellular carcinoma (HCC) and other solid tumors that were relapsed or refractory to standard treatment, according to findings from a phase 1 study (NCT03195699) published in Clinical Cancer Research.1,2 Among response-evaluable patients who received TT1-101 (n = 41)— a first-in-class, selective small-molecule...

1 week ago | onclive.com | Courtney Flaherty

The swath of agents and regimens approved for the first-line treatment of patients with advanced melanoma has muddied second-line treatment decision-making for this patient population, according to Justin Moser, MD, who added that past and ongoing clinical trials investigating immunotherapy strategies beyond checkpoint inhibition could help refine treatment strategies in this setting.